Go to the list of all blogs
Alicia's Avatar
published in Blogs
Mar 11, 2026
Why Did Fair Isaac Corp (FICO) Stock Fall Over -9% Today?

Why Did Fair Isaac Corp (FICO) Stock Fall Over -9% Today?

Fair Isaac Corp (FICO), the analytics and software company best known for its FICO credit scores and decisioning platforms, saw its stock drop more than 9% today in a sharp, broad-based selloff. The move erased a sizable chunk of recent gains and pulled the shares further below their recent highs around the low‑$2,000 range, as investors reassessed valuation, competitive risks, and market volatility. While the company’s underlying fundamentals remain solid, today’s slide highlights how quickly sentiment can turn on high‑multiple technology names.

Key Takeaways

  • FICO fell over 9% today, extending a multi‑week downtrend that has already knocked the stock more than 7% lower since its last earnings update.

  • The decline comes despite strong recent financial results, including double‑digit revenue growth, expanding margins, and repeated earnings beats.

  • A lofty valuation, with the shares trading at a rich earnings and sales multiple, has left FICO vulnerable to profit‑taking and risk‑off shifts in the broader market.

  • Sector peers and growth names also traded weaker, suggesting that part of the move reflects broader market volatility and rotation out of expensive software stocks.

  • Investors are watching closely for signs of continued competitive pressure in credit scoring and data analytics, as well as any changes to FICO’s full‑year 2026 guidance.

Beyond the day’s price action, many traders are turning to AI‑driven tools to navigate swings like this in real time. Tickeron’s AI‑powered platforms scan large universes of stocks, including names like FICO, to detect unusual volatility, trend reversals, and pattern breakouts that can precede moves of this magnitude. By automatically analyzing technical indicators, historical behavior, and correlations, these tools help users distinguish between a routine pullback in an otherwise strong uptrend and an early signal of deeper weakness. For active traders and longer‑term investors alike, AI‑based screeners, pattern‑recognition engines, and portfolio‑risk dashboards can provide an additional layer of insight when markets suddenly punish even fundamentally strong companies.

At the core of today’s selloff is a tension between FICO’s robust operating performance and the elevated expectations embedded in its share price. In its most recent reported quarter, the company delivered solid double‑digit revenue growth, expanding operating margins, and an earnings beat versus Wall Street forecasts. Revenue climbed in the mid‑teens year over year, powered by its Scores and software segments, while non‑GAAP earnings per share outpaced estimates by a high single‑digit to low double‑digit percentage. That kind of consistency has made FICO a market favorite, but it has also pushed traditional valuation measures such as the price‑to‑earnings and price‑to‑sales ratios well above historical market averages.

When valuation gets that stretched, even minor shifts in sentiment can trigger an outsized reaction in the stock. Analysts still expect strong earnings power, with consensus pointing to solid growth in fiscal 2026 and beyond, but the multiple applied to those earnings is now under pressure as investors rotate toward less expensive opportunities. Recent commentary has also highlighted competitive risks, including aggressive pricing moves by major rivals in the credit‑data and scoring space, which could eventually squeeze FICO’s economics or require higher investment to defend share. Even if such threats remain more long‑term than immediate, they add another layer of uncertainty to a stock that had been priced for near‑flawless execution.

Broader market conditions have amplified that vulnerability. Today’s decline in FICO comes amid choppy trading in major indices and heightened volatility across growth and technology shares. With a beta above the market and a history of sizable price swings, the stock tends to magnify broader risk‑off moves. High institutional ownership further concentrates price action: when large funds rebalance or trim exposure to richly valued names, the mechanical selling can accelerate a downturn, especially on days when overall risk appetite is weak. In that context, FICO’s more than 9% slide looks less like a company‑specific crisis and more like a sharp repricing of a high‑quality asset in response to shifting macro and sector dynamics.

For long‑term investors, the key question is whether today’s move marks the start of a more sustained de‑rating or a painful but ultimately temporary reset. On one hand, the company’s balance sheet, profitability metrics, and growth profile remain strong, with high operating and EBITDA margins and a solid track record of cash generation. On the other, the combination of elevated volatility, competitive noise, and a still‑demanding valuation suggests that the shares may remain sensitive to any disappointment in upcoming quarters or guidance updates. As always, the answer will depend less on a single day’s trading and more on how FICO executes against its strategic roadmap in the quarters ahead, and whether earnings growth can keep pace with — or outrun — the market’s shifting expectations.

Tickeron AI Perspective

 Disclaimers and Limitations

Related Ticker: FICO

Contributor

Alicia's AvatarAlicia|Beginner

FICO in upward trend: price may ascend as a result of having broken its lower Bollinger Band on September 29, 2026

FICO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 39 cases where FICO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where FICO advanced for three days, in 276 of 373 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FICO as a result. In 48 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.

The Moving Average Convergence Divergence Histogram (MACD) for FICO turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 33 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where FICO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.

The Aroon Indicator for FICO entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 9 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating fairly steady price growth. FICO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (82.645) is normal, around the industry mean (51.456). P/E Ratio (24.345) is within average values for comparable stocks, (82.636). Projected Growth (PEG Ratio) (0.671) is also within normal values, averaging (3.135). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.794) is also within normal values, averaging (69.875).

The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FICO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Salesforce (NYSE:CRM), Shopify Inc (NASDAQ:SHOP), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Datadog (NASDAQ:DDOG), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Workday (NASDAQ:WDAY), Atlassian Corp (NASDAQ:TEAM), Autodesk (NASDAQ:ADSK).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 9.9B. The market cap for tickers in the group ranges from 39 to 244.09B. SAPGF holds the highest valuation in this group at 244.09B. The lowest valued company is STIXF at 39.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 1%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 11%. RPGL experienced the highest price growth at 180%, while WCT experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was -45%. For the same stocks of the Industry, the average monthly volume growth was 20% and the average quarterly volume growth was -37%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 76
Price Growth Rating: 59
SMR Rating: 77
Profit Risk Rating: 94
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
FICO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of enterprise decision management solutions

Industry PackagedSoftware

Industry
Packaged Software
Address
5 West Mendenhall
Phone
+1 406 982-7276
Employees
3811
Web
https://www.fico.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.